MSD Korea, ‘Box New Vans’ advertisement on air with Baek Jong-won < Photo News < Pharmaceutical/Bio < News < Text of Article

MSD Korea (CEO Albert Kim) selected Baek Jong-won, who has been loved by the public as a loving and attentive father and successful businessman, as the advertising model for its new 15-valent pneumococcal conjugate vaccine, Box NewVance, and launched the brand to promote Box NewVance. It was announced on the 24th that advertising had begun.

This advertisement, which is broadcast through various channels such as TV and YouTube, uses the slogan ‘Vaccination Principle’ using Baek Jong-won’s name. Through this, it was explained that it is emphasized that Boxnuvans, which prevents the widest range of pneumococcal serotypes in the country and has confirmed immunogenicity for all serotypes included in the vaccine, is an option that complies with the ‘principles of pneumococcal vaccination.’

According to the company, when selecting a pneumococcal vaccine, factors such as ▲whether it is suitable for the recent disease outbreak status (prevention scope) ▲whether all serotypes have acquired sufficient immunogenicity (efficacy/effectiveness) ▲whether the vaccine can be administered with confidence (safety profile), etc. must be carefully considered. BoxNewVance confirmed that it is a vaccine suitable for these principles through a total of 12 clinical studies targeting all ages from 6 weeks of age.

First, the scope of prevention was expanded compared to existing vaccines by adding the representative serotypes 22F and 33F, which are prevalent around the world due to seroreplacement phenomenon. Therefore, it can be an effective option in line with the recent trend of pneumococcal disease outbreaks.

Immunogenicity, which indicates the effectiveness of the vaccine, is as important as the scope of prevention. In general, conjugate vaccines tend to reduce the immunogenicity of existing serotypes when new serotypes are added. Therefore, the immunogenicity of each serotype must also be examined. MSD overcame these limitations after a long period of research and development, and ‘Box New Vans’ confirmed sufficient immunogenicity at the same level in 15 individual serotypes even with the addition of 22F and 33F.

For serotype 3, superior immunogenicity was confirmed compared to existing vaccines. Serotype 3 is the main serotype causing pneumococcal disease in adults worldwide and has the characteristic of causing fatal invasive disease in children as well. It is also one of the serotypes that exhibit antibiotic resistance. Therefore, it is expected that vaccination with BoxnuVance will effectively prevent serotype 3, which has been consistently reported even with existing vaccinations.

BoxNewVance also confirmed a safety profile similar to that of existing vaccines. Based on this clinical effectiveness, Vaxnuvans has been approved and used in more than 60 countries around the world since approval by the U.S. Food and Drug Administration (FDA) in 2021, and the U.S. Advisory Committee on Immunization Practices (ACIP) has included it in the pneumococcal vaccination guidelines. Includes box new vans.

Jaeyong Cho, Executive Director of MSD Korea’s Vaccine Division, said, “We will provide consumers with accurate information about pneumococcal disease through the friendly Baek Jong-won, while further accelerating our marketing activities to increase accessibility to more effective pneumococcal vaccines among domestic consumers. “It is,” he said.